M. Berger Franklin's Insider Trades & SAST Disclosures
M. Berger Franklin's most recent trade in Atea Pharmaceuticals Inc was a trade of 15,000 Common Stock done at an average price of $3.2 . Disclosure was reported to the exchange on Jan. 15, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern M. Berger Franklin.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Atea Pharmaceuticals Inc | Franklin M. Berger | Director | Purchase of securities on an exchange or from another person at price $ 3.19 per share. | 15 Jan 2025 | 15,000 | 466,897 | - | 3.2 | 47,885 | Common Stock |
| Atea Pharmaceuticals Inc | Franklin M. Berger | Director | Purchase of securities on an exchange or from another person at price $ 3.36 per share. | 15 Jan 2025 | 10,000 | 476,897 | - | 3.4 | 33,614 | Common Stock |
| Atea Pharmaceuticals Inc | M. Berger Franklin | Director | Sale of securities on an exchange or to another person at price $ 2.85 per share. | 10 Dec 2024 | 359,606 | 451,897 | - | 2.8 | 1,023,475 | Common Stock |
| Atea Pharmaceuticals Inc | Franklin M. Berger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 41,200 | 41,200 | - | - | Stock Option (Right to Buy) | |
| Atea Pharmaceuticals Inc | Franklin M. Berger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 29,600 | 29,600 | - | - | Restricted Stock Units | |
| Kezar Life Sciences Inc | Franklin M. Berger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Atea Pharmaceuticals Inc | Franklin M. Berger | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2024 | 33,150 | 811,503 | - | 0 | Common Stock | |
| Atea Pharmaceuticals Inc | Franklin M. Berger | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2024 | 33,150 | 0 | - | - | Restricted Stock Units | |
| Essa Pharma Inc | Franklin M. Berger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2024 | 50,000 | 50,000 | - | - | Options | |
| Kezar Life Sciences Inc | Franklin M. Berger | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 26,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Franklin M. Berger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Franklin M. Berger | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 26,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Franklin M. Berger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Atea Pharmaceuticals Inc | Franklin M. Berger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 46,750 | 46,750 | - | - | Stock Option (Right to Buy) | |
| Atea Pharmaceuticals Inc | Franklin M. Berger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 33,150 | 33,150 | - | - | Restricted Stock Units | |
| Kezar Life Sciences Inc | Franklin M. Berger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Atreca Inc - Ordinary Shar... | Franklin M. Berger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | |
| Essa Pharma Inc | Franklin M. Berger | Director | Sale of securities on an exchange or to another person at price $ 2.67 per share. | 14 Dec 2022 | 50,000 | 800,244 (13%) | 0% | 2.7 | 133,500 | Common Shares |
| Essa Pharma Inc | Franklin M. Berger | Director | Sale of securities on an exchange or to another person at price $ 2.86 per share. | 14 Dec 2022 | 50,000 | 850,244 (14%) | 0% | 2.9 | 143,000 | Common Shares |
| Essa Pharma Inc | Franklin M. Berger | Director | Sale of securities on an exchange or to another person at price $ 2.53 per share. | 14 Dec 2022 | 43,617 | 756,627 (13%) | 0% | 2.5 | 110,351 | Common Shares |
| Essa Pharma Inc | Franklin M. Berger | Director | Sale of securities on an exchange or to another person at price $ 2.41 per share. | 14 Dec 2022 | 37,889 | 718,738 (12%) | 0% | 2.4 | 91,312 | Common Shares |
| Essa Pharma Inc | Franklin M. Berger | Director | Sale of securities on an exchange or to another person at price $ 2.42 per share. | 14 Dec 2022 | 34,334 | 684,404 (11%) | 0% | 2.4 | 83,088 | Common Shares |
| Essa Pharma Inc | Franklin M. Berger | Director | Sale of securities on an exchange or to another person at price $ 2.90 per share. | 14 Dec 2022 | 32,000 | 900,244 (15%) | 0% | 2.9 | 92,800 | Common Shares |
| Essa Pharma Inc | Franklin M. Berger | Director | Sale of securities on an exchange or to another person at price $ 3.00 per share. | 14 Dec 2022 | 25,000 | 932,244 (16%) | 0% | 3 | 75,000 | Common Shares |
| Rain Oncology Inc | Franklin M. Berger | Director | Purchase of securities on an exchange or from another person at price $ 8.27 per share. | 21 Nov 2022 | 77,000 | 1,005,207 | - | 8.3 | 636,790 | Common Stock |
| Rain Oncology Inc | Franklin M. Berger | Director | Purchase of securities on an exchange or from another person at price $ 7.80 per share. | 21 Nov 2022 | 45,000 | 928,207 | - | 7.8 | 351,000 | Common Stock |
| Atea Pharmaceuticals Inc | Franklin M. Berger | Director | Sale of securities on an exchange or to another person at price $ 5.15 per share. | 11 Nov 2022 | 25,500 | 794,519 | - | 5.2 | 131,333 | Common Stock |
| Atea Pharmaceuticals Inc | Franklin M. Berger | Director | Sale of securities on an exchange or to another person at price $ 5.16 per share. | 11 Nov 2022 | 16,166 | 778,353 | - | 5.2 | 83,352 | Common Stock |
| Rain Oncology Inc | Franklin M. Berger | Director | Purchase of securities on an exchange or from another person at price $ 5.83 per share. | 08 Nov 2022 | 42,881 | 883,207 | - | 5.8 | 249,996 | Common Stock |
| Essa Pharma Inc | Franklin M. Berger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2022 | 22,500 | 22,500 | - | - | Stock Option (Right to Buy) | |
| Atea Pharmaceuticals Inc | Franklin M. Berger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 61,264 | 61,264 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Franklin M. Berger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 26,000 | 26,000 | - | - | Stock Option (right to buy) | |
| Atreca Inc - Ordinary Shar... | Franklin M. Berger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | |
| Rain Oncology Inc | Franklin M. Berger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Franklin M. Berger | Director | Purchase of securities on an exchange or from another person at price $ 17.00 per share. | 18 Mar 2022 | 45,000 | 870,691 (2%) | 0% | 17 | 765,000 | Common Stock |
| Kezar Life Sciences Inc | Franklin M. Berger | Director | Purchase of securities on an exchange or from another person at price $ 14.77 per share. | 18 Mar 2022 | 20,000 | 890,691 (2%) | 0% | 14.8 | 295,400 | Common Stock |
| Kezar Life Sciences Inc | Franklin M. Berger | Director | Purchase of securities on an exchange or from another person at price $ 15.96 per share. | 18 Mar 2022 | 15,000 | 825,691 (2%) | 0% | 16.0 | 239,400 | Common Stock |
| Kezar Life Sciences Inc | Franklin M. Berger | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Sep 2021 | 8,896 | 0 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Franklin M. Berger | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Sep 2021 | 8,896 | 0 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Franklin M. Berger | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.91 per share. | 21 Sep 2021 | 8,896 | 792,899 (2%) | 0% | 5.9 | 52,575 | Common Stock |
| Kezar Life Sciences Inc | Franklin M. Berger | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.63 per share. | 21 Sep 2021 | 8,896 | 801,795 (2%) | 0% | 7.6 | 67,876 | Common Stock |
| Kezar Life Sciences Inc | Franklin M. Berger | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.60 per share. | 21 Sep 2021 | 8,896 | 810,691 (2%) | 0% | 5.6 | 49,818 | Common Stock |
| Kezar Life Sciences Inc | Franklin M. Berger | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Sep 2021 | 8,896 | 0 | - | - | Stock Option (Right to Buy) | |
| Rain Oncology Inc | Franklin M. Berger | Director | Purchase of securities on an exchange or from another person at price $ 14.30 per share. | 21 Sep 2021 | 3,786 | 840,326 | - | 14.3 | 54,140 | Common Stock |
| Kezar Life Sciences Inc | Franklin M. Berger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2021 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Atreca Inc - Ordinary Shar... | Franklin M. Berger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | |
| Rain Oncology Inc | Franklin M. Berger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 24,000 | 24,000 | - | - | Stock Option (Right to Buy) | |
| Rain Oncology Inc | Franklin M. Berger | Director | 23 Apr 2021 | 578,397 | 0 | - | - | Series B Preferred Stock | ||
| Rain Oncology Inc | Franklin M. Berger | Director | 23 Apr 2021 | 535,601 | 836,540 | - | - | Common Stock | ||
| Rain Oncology Inc | Franklin M. Berger | Director | 23 Apr 2021 | 189,998 | 0 | - | - | Series A Preferred Stock | ||
| Rain Oncology Inc | Franklin M. Berger | Director | 23 Apr 2021 | 175,939 | 300,939 | - | - | Common Stock | ||
| Rain Oncology Inc | Franklin M. Berger | Director | Purchase of securities on an exchange or from another person at price $ 17.00 per share. | 23 Apr 2021 | 120,000 | 120,000 | - | 17 | 2,040,000 | Common Stock |
| Rain Oncology Inc | Franklin M. Berger | Director | Purchase of securities on an exchange or from another person at price $ 15.78 per share. | 23 Apr 2021 | 5,000 | 125,000 | - | 15.8 | 78,900 | Common Stock |
| Essa Pharma Inc | Franklin M. Berger | Director | Purchase of securities on an exchange or from another person at price $ 27.00 per share. | 22 Feb 2021 | 57,000 | 957,244 (16%) | 0% | 27 | 1,539,000 | Common Shares |
| Atea Pharmaceuticals Inc | Franklin M. Berger | Director | 03 Nov 2020 | 759,606 | 778,353 | - | - | Common Stock | ||
| Atea Pharmaceuticals Inc | Franklin M. Berger | Director | 03 Nov 2020 | 400,000 | 0 | - | - | Series A Convertible Preferred Stock | ||
| Atea Pharmaceuticals Inc | Franklin M. Berger | Director | 03 Nov 2020 | 132,014 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Atea Pharmaceuticals Inc | Franklin M. Berger | Director | 03 Nov 2020 | 131,578 | 0 | - | - | Series C Convertible Preferred Stock | ||
| Atea Pharmaceuticals Inc | Franklin M. Berger | Director | 03 Nov 2020 | 60,540 | 0 | - | - | Series D Convertible Preferred Stock | ||
| Atea Pharmaceuticals Inc | Franklin M. Berger | Director | Purchase of securities on an exchange or from another person at price $ 24.00 per share. | 03 Nov 2020 | 41,666 | 820,019 | - | 24 | 999,984 | Common Stock |
| Atea Pharmaceuticals Inc | Franklin M. Berger | Director | 03 Nov 2020 | 35,474 | 0 | - | - | Series D-1 Convertible Preferred Stock | ||
| Atea Pharmaceuticals Inc | Franklin M. Berger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Oct 2020 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Franklin M. Berger | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2020 | 8,896 | 8,896 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Franklin M. Berger | None | Purchase of securities on an exchange or from another person at price $ 5.50 per share. | 11 Jun 2020 | 100,000 | 784,003 (2%) | 0% | 5.5 | 550,000 | Common Stock |
| Atreca Inc - Ordinary Shar... | Franklin M. Berger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2020 | 12,000 | 12,000 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges